2nd Microbiome Drug Development Summit Europe

2nd Microbiome Drug Development Summit Europe is organized by Hanson Wade and will be held during Jan 29 - Feb 01, 2018 at Hyatt Regency Paris Etoile, Paris, Ile-de-France, France.

Situated at the heart of therapeutic R and D, the Microbiome Drug Development Summit kick starts 2018, once again to help large pharma, biotech and academic institutions accelerate the discovery, clinical development of safe, effective and commercially scalable microbiome therapeutics across a broad range of disease indications.

Set to tackle the greatest scientific, regulatory, clinical, manufacturing and commercialization challenges across the entire drug development value chain, Microbiome Drug Development Summit Europe will showcase leading industry case studies focused on enhancing the application of novel technologies to standardise results, accelerate target discovery and optimise the translation of microbiome research into safe and effective therapeutic products.

Being part of the Microbiome Drug Development Summit gives you the opportunity to get unprecedented access to the latest preclinical, clinical and commercial case studies from the brightest minds in biopharma and academia to turn microbiome discoveries of today into patient therapies of the future.

Visit microbiome-europe.com to see how leading researchers are addressing unique scientific and product developmental challenges when bringing about a new age of microbiome-based therapeutics.

Prices:
Industry Conference Only: EUR 2199,
Academic Conference Only: EUR 1699.

Speakers: Outi Vaarala (VP Head of Translational Biology at AstraZeneca), Olga Danilchanka (Microbiome Lead; Exploratory Science Center (ESC) at Merck), Laurence Zitvogel (Professor at Institut Gustave Roussy), Lee Jones (CEO at Rebiotix), Kristin Wannerberger (Director RandD Alliance Management at Ferring Pharmaceuticals), John Aunins (EVP of Manufacturing and Chief Technology Officer at Seres Therapeutics), Jim Brown (Director Computational Biology at GSK), Daniel van der Lelie (Chief Scientific Officer at Gusto Global), Christian Freguia (Director of Research at Synthetic Biologics).

Additional details will be posted as soon as they are available.